Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?
about
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSDeveloping Combined HIV Vaccine Strategies for a Functional CureRecent developments in clinical trial designs for HIV vaccine researchWillingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in ChinaBroadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvantThe Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDSHIV-1 transcription and latency: an update.Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsElimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.Lessons learned from HIV vaccine clinical efficacy trials.The many lives of CTIP2: from AIDS to cancer and cardiac hypertrophy.A cure for AIDS: a matter of timing?A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsDendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine.Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs LieA Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Effects of exosome on the activation of CD4+ T cells in rhesus macaques: a potential application for HIV latency reactivation.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Advances in dendritic cell immunotherapies for HIV-1 infection.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.Polyhydroxylated Metallofullerenols Stimulate IL-1β Secretion of Macrophage through TLRs/MyD88/NF-κB Pathway and NLRP3Inflammasome Activation
P2860
Q26777442-20F2AABC-AEED-457F-8BF6-2CF3A6634528Q26866145-148F675E-6C00-40B2-A9D1-6BE73AEA7ECFQ26998898-11C19951-14DD-4027-A124-0E159F36607DQ28083514-6D6B67A9-7093-4BAB-8FC5-6CA3EDD6A33CQ28544731-9CFC4D47-F040-427F-8528-BB51A97AFD57Q34730713-29748B43-68EB-45B4-9308-3E84F95BACACQ36080407-EB2BD223-C408-4931-BAA5-BA8C42CA37D8Q36613666-24A735AF-F534-4D65-A068-12ED533ED2CBQ36976156-0E9ABA1A-0D87-4AF8-8F8F-496CD620EFF0Q37273652-01B38DAB-7F02-491E-99ED-9DF0E9F3523CQ37499526-BB1991E7-B4E8-4DE3-9BA2-6F76819DE50FQ37724091-9C4ADA28-C84D-4A03-901A-FA7136D35ED0Q38152295-A3498FD5-8277-4FCD-A289-DA83AAFBC659Q38165451-84402CC4-B02E-4D8A-833C-73225B754932Q38206520-6AC06E23-1FE7-4EAD-B9FA-86CE6F51392AQ38296086-BAA3C2FC-236B-4E2F-AC83-A86044C8C6BBQ38856258-9925053A-D6C0-4648-AAC2-D8E8B014360EQ39201703-F76AB802-9A44-43C3-949E-7B38067803A7Q40919787-77CE3410-F665-4ADF-A351-2F323EAF6E26Q45908717-C4B2A276-A15C-4D18-BFDF-5A149C278837Q47548487-73C8053D-FF35-4A67-9FF0-CD9B5DA2EBF6Q51217825-10400848-94E9-400B-B29A-D3D08C8BF3F5Q55154648-E8226AE6-3F8A-42F0-B25E-68CD12F2C868Q58068781-441568C5-3BDD-477C-AAD6-9E68A5548FFA
P2860
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@ast
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@en
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@nl
type
label
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@ast
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@en
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@nl
prefLabel
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@ast
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@en
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@nl
P2860
P921
P3181
P356
P1433
P1476
Can immunotherapy be useful as ...... uman Immunodeficiency Virus-1?
@en
P2093
Ellen Van Gulck
Guido Vanham
P2860
P2888
P3181
P356
10.1186/1742-4690-9-72
P407
P5008
P577
2012-09-07T00:00:00Z
P5875
P6179
1040138485